The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
13 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $18,162,953 in first-year total cost, median $1,464,451.
Most frequent study sections
- Special Emphasis Panel[ZRG1 IMST-K (19)]10
- Special Emphasis Panel[ZRG1 MCST-K (19)]2
- Special Emphasis Panel[ZRG1 IMST-K (18)]1
Most frequent institutions
- AMYDIS DIAGNOSTICS, INC.2
- ACETAMINOPHEN TOXICITY DIAGNOSTICS, LLC1
- ADVANCED MEDICAL ELECTRONICS CORPORATION1
- BONE HEALTH TECHNOLOGIES, INC.1
- COGNITION THERAPEUTICS, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Clinical study to enable commercialization of nonsurgical gel patch for eardrum repair2SB1DC018255-02 | HORN-RANNEY, ELAINE LARKIE | TYMPANOGEN, LLC, VA | $3,235,980 | ZRG1 |
| 2023 | Commercialization of an Improved Treatment of Extremity Fractures Using a Regenerative Bone Adhesive to Accelerate Bone Healing in Aging Patients1SB1AG085803-01 | HESS, BRIAN | REVBIO, INC., MA | $1,746,739 | ZRG1 |
| 2023 | Use of novel fluorescent tracers to develop a comprehensive retinal biomarker database that maps the heterogeneity of Alzheimer's pathogenesis2SB1AG050454-04A1 | SARRAF, STELLA | AMYDIS DIAGNOSTICS, INC., CA | $1,704,372 | ZRG1 |
| 2022 | AcetaSTAT Validation and Commercialization2SB1DK079387-09A1 | JAMES, LAURA P | ACETAMINOPHEN TOXICITY DIAGNOSTICS, LLC, AR | $1,069,721 | ZRG1 |
| 2022 | REMI Platform for Remote EEG Monitoring2SB1NS100235-05A1 | LEHMKUHLE, MARK J. | EPITEL, INC., UT | $1,053,438 | ZRG1 |
| 2022 | Commercial Readiness of a CI NR algorithm2SB1DC018761-03 | LANDSBERGER, DAVID MSOLEYMANI, ROOZBEH | YORK SOUND INC, NY | $1,020,715 | ZRG1 |
| 2022 | Compatibility Between Brain-Computer Interface and High Efficiency Augmentative and Alternative Communication Systems: Commercial Readiness2SB1DC015142-04 | HILL, KATYA JHUGGINS, JANE EMALCOMSON, SHAWN | PRENTKE ROMICH COMPANY, OH | $965,218 | ZRG1 |
| 2022 | Enhanced Imaging for Visual Prostheses2SB1EY024498-04A1 | SEIFERT, GREGORY JOHN | ADVANCED MEDICAL ELECTRONICS CORPORATION, MN | $731,134 | ZRG1 |
| 2021 | Human AME study of CT1812, a small molecule in phase 2 clinical trials for the treatment of Alzheimer's disease1SB1AG073028-01A1 | CAGGIANO, ANTHONY O | COGNITION THERAPEUTICS, INC., PA | $1,642,783 | ZRG1 |
| 2021 | Development of an ophthalmic diagnostic probe for cerebral amyloid angiopathy in patients1SB1AG073029-01A1 | SARRAF, STELLA | AMYDIS DIAGNOSTICS, INC., CA | $1,590,883 | ZRG1 |
| 2021 | Commercializing In-Home Supportive Technolgy for Dementia Caregivers2SB1AG059458-04A1 | WANG, GENE | PEOPLE POWER COMPANY, WA | $1,567,178 | ZRG1 |
| 2021 | Wearable Vibration Device to Prevent Bone Loss in Postmenopausal Women2SB1AG046005-04 | HILLSTROM, DEREK | BONE HEALTH TECHNOLOGIES, INC., CA | $1,464,451 | ZRG1 |
| 2021 | Evaluation of clinical outcome assessment (COA) and potential biomarkers to Facilitate Interventionaltrial for Mucopolysaccharidosis IIID Patients1UB1NS122644-01A1 | SINGAMSETTY, SRIKANTH | PHOENIX NEST, INC., NY | $370,341 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.